The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).
A. M. Traynor
No relevant relationships to disclose
J. Kolesar
No relevant relationships to disclose
R. M. Marnocha
No relevant relationships to disclose
J. C. Eikhoff
No relevant relationships to disclose
D. B. Alberti
No relevant relationships to disclose
N. Takebe
No relevant relationships to disclose
G. Wilding
No relevant relationships to disclose
G. Liu
No relevant relationships to disclose
W. R. Schelman
No relevant relationships to disclose